Sibutramine (Meridia, Reductil)
Withdrawn appetite-suppressant drug: pulled in 2010 over heart risks, and now turns up undeclared in “herbal” slimming products.

The links above are labelled third-party affiliate links. MolekulaX does not sell and does not verify product quality.

DETAILED OVERVIEW
What is Sibutramine (Meridia, Reductil)?
Sibutramine was once a prescription slimming drug, sold from 1997 as Meridia (US) and Reductil (Europe). It blocks the reuptake of serotonin and norepinephrine, two brain messengers, so fullness arrives sooner and body weight falls measurably.
In a large trial, patients at high cardiovascular risk had more non-fatal heart attacks and strokes than on placebo, so the drug was withdrawn in 2010. Losing weight itself did no harm: the damage came from the drug’s norepinephrine effect, which raises blood pressure and heart rate. Together with some antidepressants, migraine drugs and MAO inhibitors it can cause life-threatening serotonin syndrome. It must not be used in heart disease or pregnancy. Today it matters mainly because it is the most common undeclared adulterant in “herbal” slimming products, so users cannot know what they are taking. It is banned as a stimulant in competition.
Mechanism
Serotonin and norepinephrine reuptake inhibition, increased satiety.
Why it was withdrawn
More non-fatal heart attacks and strokes than with placebo (10,744 patients)
Date of withdrawal
EMA January 2010, FDA October 2010. No longer marketed anywhere as an approved drug.
Relevance today
The most common undeclared adulterant in "herbal" slimming products.
Half-life
Active metabolites ~14-16 h, hence once-daily dosing.
No anecdote collected yet.
Data console
Lab data
Caterson ID, Finer N, Coutinho W . Maintained intentional weight loss reduces cardiovascular outcomes: results from the Sibutramine Cardiovascular OUTcomes (SCOUT) trial.. Diabetes, obesity & metabolism.
Maggioni AP, Caterson I, Coutinho W . Tolerability of sibutramine during a 6-week treatment period in high-risk patients with cardiovascular disease and/or diabetes: a preliminary analysis of the Sibutramine Cardiovascular Outcomes (SCOUT) Trial.. Journal of cardiovascular pharmacology.
Scheen AJ . Cardiovascular risk-benefit profile of sibutramine.. American journal of cardiovascular drugs : drugs, devices, and other interventions.
Hainer V, Aldhoon-Hainerová I . Tolerability and safety of the new anti-obesity medications.. Drug safety.
Safety
Side effects, stop signs, contraindications
Side effects · 5
- Rising blood pressure and heart rate: a direct consequence of the noradrenergic action, and precisely what led to withdrawal of the approval.
- Increased cardiovascular events: in SCOUT, non-fatal myocardial infarction and stroke were more frequent than on placebo.
- Risk of serotonin syndrome: combined with an SSRI, SNRI, triptan or MAO inhibitor it can be life-threatening.
- Insomnia, dry mouth, constipation, anxiety and irritability: the most common, dose-dependent complaints.
- Undeclared presence in slimming products: users often do not know they are taking it, making interactions and cardiac risk impossible to guard against.
Contraindications · 5
- Any known cardiovascular disease: coronary disease, prior infarction or stroke, heart failure, arrhythmia. SCOUT demonstrated harm in exactly this population.
- Untreated or poorly controlled hypertension.
- Concurrent serotonergic medication (SSRI, SNRI, triptan, MAO inhibitor, tramadol): risk of serotonin syndrome.
- Pregnancy and breastfeeding, as well as hyperthyroidism and narrow-angle glaucoma.
- Competitive sport under testing: WADA bans stimulants in competition (S6).
Related Performance Compounds
Same therapeutic category
Studies
Related research and clinical findings
Maintained intentional weight loss reduces cardiovascular outcomes: results from the Sibutramine Cardiovascular OUTcomes (SCOUT) trial.
Caterson ID, Finer N, Coutinho W
Tolerability of sibutramine during a 6-week treatment period in high-risk patients with cardiovascular disease and/or diabetes: a preliminary analysis of the Sibutramine Cardiovascular Outcomes (SCOUT) Trial.
Maggioni AP, Caterson I, Coutinho W
Cardiovascular risk-benefit profile of sibutramine.
Scheen AJ
Tolerability and safety of the new anti-obesity medications.
Hainer V, Aldhoon-Hainerová I
Telegram
Have a question about Sibutramine (Meridia, Reductil)?
Reach out to an advisor on Telegram. Performance compounds are presented with a harm-reduction approach, based on peer-reviewed evidence.
Personalized consultation
Want a detailed conversation tailored to your data?
Fill out the prep intake form (your goals, training and health data), and the advisor prepares from it to give genuinely personalized guidance.
Fill out the form~5–7 min · prep questionnaire · confidential · GDPR-compliant
The information here is for educational and scientific purposes only. Performance-enhancing compounds (AAS, prohormones, stimulants, doping agents) are illegal without prescription in Hungary and most of the EU, and carry serious health and legal risks. WADA bans them in competitive sport. This is NOT a usage guide, and we do not encourage any illegal use. If you do use them, medical supervision and regular bloodwork are ESSENTIAL. Severe endocrine, cardiovascular, hepatic and psychiatric side effects are possible.